Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00083187 · ClinicalTrials.gov registry record · Phase 2
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia
A Phase 2 study, sponsored by Vion Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 230
- Enrollment target
NCT00083187: Completed Phase 2 study, sponsored by Vion Pharmaceuticals.
NCT00083187 is a Phase 2 study that has completed, run by Vion Pharmaceuticals. The registered enrollment target is 230 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00083187, a Phase 2 study, has completed, sponsored by Vion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 230 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as VNP40101M and hydroxyurea, work in different ways to stop cancer cells from dividing so they stop growing or die. Hydroxyurea may help VNP40101M kill more cancer cells by making cancer cells more sensitive to the drug. PURPOSE: This phase II trial is studying how well giving VNP40101M with hydroxyurea works in treating patients with acute myelogenous leukemia or high-risk myelodysplasia.
Interventions
- DRUG hydroxyurea
- DRUG laromustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-08 |
| Phase | Phase 2 |
What the finished NCT00083187 record still lists
NCT00083187 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (73% higher).
The record links to 0 conditions, and to 2 interventions - of which hydroxyurea is the first listed.
NCT00083187 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00083187 about?
NCT00083187 is a clinical study titled "VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia". RATIONALE: Drugs used in chemotherapy, such as VNP40101M and hydroxyurea, work in different ways to stop cancer cells from dividing so they stop growing or die. Hydroxyurea may help VNP40101M kill more cancer cells by making cancer cells more sensitive to the drug. PURPOSE: This phase II trial is s...
What is the current status of trial NCT00083187?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 230 participants. The study started on 2005-11. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00083187?
The interventions under investigation include: hydroxyurea (DRUG), laromustine (DRUG).
Who is sponsoring clinical trial NCT00083187?
This trial is sponsored by Vion Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00083187's enrollment target sits among peer trials
230 257th of 2000 higher than 1,737 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia